Overview

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
WAYFINDER is a Phase 1/2 study in Australia to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 36 to <84 months (3 to <7 years). The study follows an open-label, dose-escalation design.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Encoded Therapeutics